Abstract
BackgroundCurrently approved biomarkers that predict response to ICIs in mNSCLC are limited to PD-L1 expression levels by immunohistochemistry (IHC) and tumor mutation burden (TMB). However, the predictive performance of PD-L1...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have